Key statistics
As of last trade Travere Therapeutics Inc (17R:BER) traded at 17.60, -6.88% below its 52-week high of 18.90, set on Nov 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.50 |
---|---|
High | 17.60 |
Low | 17.40 |
Bid | 17.10 |
Offer | 18.20 |
Previous close | 17.50 |
Average volume | 294.33 |
---|---|
Shares outstanding | 85.72m |
Free float | 85.06m |
P/E (TTM) | -- |
Market cap | 1.57bn USD |
EPS (TTM) | -4.52 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 12:55 GMT.
More ▼
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
- Travere Therapeutics Announces Pricing of Public Offering of Common Stock
- Travere Therapeutics Announces Proposed Public Offering of Common Stock
- Travere Therapeutics to Present at Upcoming Investor Conferences
- Travere Therapeutics Reports Third Quarter 2024 Financial Results
- Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
- Travere Therapeutics to Report Third Quarter 2024 Financial Results
- Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
- Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
More ▼